COVID-19疫苗接种对757万成人及24.1万青少年接种者甲状腺疾病的影响
该研究基于韩国全国性自控病例系列设计,纳入7579210名成人和241063名青少年疫苗接种者,评估接种后55天内甲状腺疾病发病风险。成人中甲状腺功能减退症加重风险升高,但大多数其他甲状腺疾病风险未见增加;青少年中未观察到甲状腺疾病风险增加。
要点
- 成人接种后甲状腺功能减退症加重风险升高,但甲状腺功能亢进症、亚急性甲状腺炎等风险未显著增加。
- 青少年(12-17岁)接种后未观察到甲状腺疾病风险增加。
- 基于年龄、性别和疫苗类型的亚组分析显示甲状腺疾病发生率无显著差异。
核心结论
- 这项全国性自控病例系列分析发现COVID-19疫苗接种后甲状腺功能减退症加重风险增加,但大多数其他甲状腺疾病风险未见增加;这些发现为支持COVID-19疫苗甲状腺健康安全性增加了证据。
研究设计与样本
- 采用自控病例系列设计,纳入韩国7579210名成人及241063名青少年疫苗受试者,使用条件泊松回归估计接种后55天(第一剂和第二剂)相较于未暴露期的甲状腺疾病发病率比(IRR)。
主要发现
- 成人第一剂后甲状腺功能亢进症IRR为0.98(95%CI 0.89-1.09),甲状腺功能减退症IRR为0.88(95%CI 0.84-0.93),亚急性甲状腺炎IRR为1.27(95%CI 0.94-1.72),甲状腺眼病IRR为0.68(95%CI 0.50-0.93)。
- 成人第二剂后甲状腺功能亢进症IRR为0.96(95%CI 0.87-1.06),甲状腺功能减退症IRR为0.96(95%CI 0.92-1.02),亚急性甲状腺炎IRR为1.32(95%CI 0.96-1.80),甲状腺眼病IRR为1.06(95%CI 0.81-1.38)。
- 接种后甲状腺功能亢进症复发风险未增加,但观察到甲状腺功能减退症加重风险增加。
- 基于年龄、性别和疫苗类型的亚组分析显示甲状腺疾病发生率无显著差异。
- 12至17岁青少年接种后未观察到甲状腺疾病风险增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Emerging reports have raised concerns regarding the potential association between COVID-19 vaccination and thyroid dysfunction, specifically thyroiditis. OBJECTIVE: This study aimed to investigate the potential association between COVID-19 vaccination and thyroid diseases using data from a nationwide cohort of South Korea. METHODS: This study included 7 579 210 adult and 241 063 adolescent vaccine recipients. A self-controlled case series design was applied to estimate the incidence rate ratio (IRR) of thyroid disease during the 55-day postvaccination period (first and second dose) compared to the baseline period (nonexposure period) using conditional Poisson regression. RESULTS: In the adult population, IRRs for hyperthyroidism, hypothyroidism, subacute thyroiditis, and thyroid eye disease were 0.98 (95% CI, 0.89-1.09), 0.88 (95% CI, 0.84-0.93), 1.27 (95% CI, 0.94-1.72), and 0.68 (95% CI, 0.50-0.93) after the first vaccine dose and 0.96 (95% CI, 0.87-1.06), 0.96 (95% CI, 0.92-1.02), 1.32 (95% CI, 0.96-1.80), and 1.06 (95% CI, 0.81-1.38) after the second vaccine dose. While the risk of hyperthyroidism recurrence did not increase after vaccination, we observed an increased risk of hypothyroidism exacerbation. Subgroup analyses based on age, sex, and vaccine type revealed no significant differences in the incidence of thyroid diseases. In adolescents aged 12 to 17 years, no increase in the risk of thyroid disease was observed after vaccination. CONCLUSION: This extensive, national self-controlled case series analysis found an increased risk of exacerbation of hypothyroidism following COVID-19 vaccination. However, no association was observed between COVID-19 vaccination and an increased risk of most other thyroid diseases. These findings contribute to increasing evidence supporting the safety of COVID-19 vaccination in relation to thyroid health.
引用
- Bea S, Ahn HY, Woo J, et al. Effect of COVID-19 Vaccination on Thyroid Disease in 7 Million Adult and 0.2 Million Adolescent Vaccine Recipients. J Clin Endocrinol Metab. 2025. PMID: 39657695. doi:10.1210/clinem/dgae858
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。